Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x100px
Person › Details

Stéphane Boissel (SparingVision SAS)

Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)


Organisations Organisation SparingVision SAS
  Former/major organisation TxCell S.A. (Euronext Paris: TXCL)
Products Product SPVN06 mutation-agnostic AAV gene therapy for ofretinitis pigmentosa (SparingVision)
  Product 2 gene therapy

Record changed: 2023-07-12


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Stéphane Boissel

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top